Clinical bottom line
Circulating tumor DNA (ctDNA) analysis is an emerging tool with potential to guide treatment adaptation in metastatic triple-negative breast cancer (mTNBC). Early dynamic changes in ctDNA levels during systemic therapy may predict prognosis and treatment response, offering a noninvasive biomarker to tailor therapy intensity. However, current evidence remains preliminary and hypothesis-generating, warranting prospective validation before routine clinical implementation.
What the evidence shows
Recent prospective studies have explored the utility of ctDNA dynamics as a biomarker in mTNBC. Yang et al. (2023) conducted a prospective analysis demonstrating that early decreases in ctDNA levels during treatment correlated with improved progression-free survival and overall survival, suggesting ctDNA as a real-time indicator of therapeutic efficacy. This study highlighted that patients with persistently high or rising ctDNA after initial cycles had poorer outcomes, indicating potential for early treatment modification.
Similarly, Zivanovic Bujak et al. (2018) reported that baseline ctDNA positivity and its clearance during therapy were associated with prognosis in mTNBC, supporting ctDNA’s role in risk stratification. Sun et al. (2023) reviewed ctDNA as a novel biomarker optimizing treatment selection, emphasizing its promise for monitoring minimal residual disease and detecting emerging resistance mutations, which could inform timely therapeutic switches.
These findings collectively suggest that ctDNA-guided treatment adaptation could enable more personalized management in mTNBC, a subtype with limited targeted options and aggressive clinical behavior. By integrating ctDNA monitoring, clinicians may identify non-responders early and consider alternative regimens or clinical trial enrollment.
Caveats and uncertainty
Despite encouraging data, several limitations temper enthusiasm for immediate clinical adoption. The studies to date have relatively small sample sizes and heterogeneous treatment regimens, limiting generalizability. Standardization of ctDNA assays, including sensitivity, specificity, and timing of sampling, remains a challenge. Moreover, the optimal ctDNA thresholds for action and the clinical benefit of treatment changes based on ctDNA dynamics have not been definitively established.
Confounding factors such as tumor heterogeneity, clonal hematopoiesis, and technical variability in ctDNA detection may affect interpretation. Additionally, prospective randomized trials demonstrating improved patient outcomes from ctDNA-guided treatment adaptation are lacking. Thus, current evidence is hypothesis-generating rather than practice-changing.
How this may change practice
If validated in larger, controlled studies, ctDNA-guided treatment adaptation could transform mTNBC management by providing a minimally invasive biomarker to monitor response and detect resistance earlier than conventional imaging. This approach may facilitate personalized therapy intensification or de-escalation, improving outcomes and sparing toxicity.
In clinical practice, serial ctDNA measurements could complement radiographic assessment, especially when imaging is ambiguous or delayed. Integration of ctDNA analysis into multidisciplinary care pathways and clinical trials may accelerate precision oncology advances for mTNBC. However, until robust prospective evidence confirms clinical utility and cost-effectiveness, ctDNA-guided treatment adaptation should remain investigational and confined to research settings.